Venlafaxine

Generic Name: Venlafaxine

Brand Names: Effexor

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₇NO_₂

CAS Number: 93413-69-5

Unique Ingredient Identifier: GRZ5RCB1QG

Background: Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...

Indication: Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.

Associated Conditions: Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

A Safety, Efficacy and Tolerability Study of SEP-225289

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: SEP-225289
Drug: placebo
Drug: Venlafaxine

First Posted Date: 2008-01-02

Last Posted Date: 2012-02-23

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 523

Registration Number: NCT00584974

Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: SSRI
Drug: Effexor

First Posted Date: 2007-05-17

Last Posted Date: 2012-03-05

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 1151

Registration Number: NCT00474708

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

Phase 2

Completed

Conditions: Depressive Disorder

Interventions: Drug: placebo
Drug: GSK372475
Drug: venlafaxine

First Posted Date: 2007-03-15

Last Posted Date: 2014-10-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 396

Registration Number: NCT00448058

Locations: 🇿🇦
GSK Investigational Site, Vereeniging, South Africa

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Phase 3

Completed

Conditions: Major Depressive Disorder
Insomnia

Interventions: Drug: Placebo
Drug: Eszopiclone
Drug: Venlafaxine

First Posted Date: 2007-02-14

Last Posted Date: 2012-02-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 678

Registration Number: NCT00435279

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Phase 3

Terminated

Conditions: Hot Flashes
Prostate Cancer

Interventions: Dietary Supplement: Placebo Powder
Drug: Venlafaxine
Dietary Supplement: oral soy protein/isoflavones powder
Drug: Placebo Pill

First Posted Date: 2006-07-20

Last Posted Date: 2021-09-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 120

Registration Number: NCT00354432

Locations: 🇺🇸
CCOP - Heartland Research Consortium, Saint Louis, Missouri, United States
🇺🇸
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 17 locations

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2006-07-13

Last Posted Date: 2011-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 494

Registration Number: NCT00351910

Locations: 🇸🇪
Research Site, Uppsala, Sweden

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

Phase 4

Completed

Conditions: Social Phobia

Interventions: Drug: Sertraline
Drug: Venlafaxine
Drug: Placebo
Drug: Clonazepam

First Posted Date: 2006-01-27

Last Posted Date: 2013-10-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 397

Registration Number: NCT00282828

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States
🇨🇦
McMaster University Medical Centre Anxiety Disorders Clinic, Hamilton, Ontario, Canada
🇺🇸
Center for Anxiety and Traumatic Stress Disorders, Boston, Massachusetts, United States

Venlafaxine Augmentation in Treatment Resistant Depression

Phase 4

Completed

Conditions: Depression

Interventions: Drug: Venlafaxine
Drug: Quetiapine

First Posted Date: 2005-11-15

Last Posted Date: 2015-04-08

Lead Sponsor: Max-Planck-Institute of Psychiatry

Target Recruit Count: 126

Registration Number: NCT00253266

Locations: 🇩🇪
Max Planck Institute of Psychiatry, Munich, Bavaria, Germany

Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals

Phase 2

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: Placebo
Drug: Venlafaxine

First Posted Date: 2005-11-07

Last Posted Date: 2017-07-11

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 150

Registration Number: NCT00249483

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Psychosocial and Medication Treatment for Anxiety in Alcoholism

Phase 2

Completed

Conditions: Alcohol-Related Disorders
Anxiety Disorders

Interventions: Drug: Venlafaxine
Other: Placebo medication
Behavioral: CBT
Other: Progressive muscle relaxation therapy (PMR)

First Posted Date: 2005-11-04

Last Posted Date: 2018-01-24

Lead Sponsor: Boston Medical Center

Target Recruit Count: 162

Registration Number: NCT00248612

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Center for Anxiety and Related Disorders, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy